Mass cytometry analysis of blood immune cells from psoriasis patients on biological therapy. Issue 3 (21st January 2021)

• Record Type: Journal Article
• Authors: Solberg, Silje Michelsen; Aarebrot, Anders Krogh; Sarkar, Irene; Petrovic, Aleksandra; Sandvik, Lene Frøyen; Bergum, Brith; Jonsson, Roland; Bryceson, Yenan Troy; Appel, Silke
• Is Part Of: European journal of immunology. Volume 51:Issue 3(2021)
• Page Start: 694
• Page End: 702
• Publication Date: 2021-01-21
• Subjects: Biological therapy -- Cardiovascular risk -- Mass cytometry -- PD‐1 -- Psoriasis -- Systemic inflammation; Immunology -- Periodicals; 616.079
• DOI: 10.1002/eji.202048857
• Languages: English
• ISSNs: 0014-2980

Abstract

Abstract: Psoriasis is a chronic immune‐mediated skin disease accompanied by systemic inflammation and comorbidities. We analyzed peripheral blood mononuclear cells (PBMCs) in the search for immune signatures and biomarkers related to psoriasis severity and treatment effect. Thirty‐two patients with psoriasis and 10 matched healthy controls were included. PBMCs were collected before and after initiation of anti‐TNF, anti‐IL‐17 or anti‐IL‐12/23 treatment and analyzed utilizing 26‐parameter mass cytometry. The number of circulating Th17, Th22, Th9, and cytotoxic T cells were increased in severe psoriasis. Intracellular pp38 and pERK in T helper cells were associated with disease severity. Differences between responders and nonresponders regarding cell composition and intracellular signaling were identifiable already at inclusion. Biological treatment induced memory cells, restored inhibitory PD‐1 function of T cells, and reduced a potential pro‐atherogenic profile in monocytes. In conclusion, these results indicate amelioration of systemic inflammation in psoriasis after biological treatment. Such broad immune profiling may enable prospective stratification of patients regarding future treatment response. Successful early intervention may lead to a healthier trajectory with favorable implications on later comorbidities. Abstract : Patients with severe psoriasis have alterations in peripheral immune cells that are restored upon biological treatment, indicating amelioration of systemic inflammation after biological treatment.